Robert J. Gould, President & CEO at Epizyme, Inc. (EPZM), sold 60,000 shares at $19.87 ($1.2M) on 2015-09-08, disclosed to the SEC on 2015-09-10.
Scheduled sale ($1.2M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.25 | 700 | $13K | 1.1% |
| 2 | $19.87 | 59,300 | $1.2M | 98.9% |
| Total | $19.86 avg | 60,000 | $1.2M | 100% |
| Filing → |
| FULC | SELL | 2026-01-06 | $356K | — | Filing → |
| FULC | SELL | 2025-11-21 | $165K | — | Filing → |
| FULC | SELL | 2023-01-13 | $101K | — | Filing → |